Prediction of Baseline Quantitative Indexes of F-18 FDG PET/CT to Outcome in Adult Non Hodgkin Lymphoma | ||
| Egyptian Journal Nuclear Medicine | ||
| Article 6, Volume 21, Issue 2, December 2020, Pages 64-79 PDF (618.09 K) | ||
| Document Type: Original Paper, PET/CT | ||
| DOI: 10.21608/egyjnm.2020.140417 | ||
| Authors | ||
| Mehesen, M1; Matter, M1; Moustafa, H2; Fathy, H1 | ||
| 1Nuclear Medicine Unit, NCI, Egypt. | ||
| 2Nuclear Medicine Unit, Faculty of Medicine, Cairo University, Cairo, Egypt. | ||
| Abstract | ||
| Purpose: The aim of this study was to investigate the effectiveness of initial quantitative indexes of FDG PET 18F-FDG PET/CT in adult Non Hodgkin Lymphoma patients on therapy outcome. Patients and Methods: A total of 57 adult patients initially diagnosed with non-Hodgkin Lymphoma were retrospectively analyzed in this study within period of January 2018 till December 2019. Initial 18F-FDG PET/CT scan was done before chemotherapy, interim 18F-FDG PET/CT done after receiving two cycles of chemotherapy. SUV max, SUV mean SUV peak, MTV, and TLG was extracted from both initial and interim 18F-FDG PET /CT scans and recorded. Follow up period was 6 – 24 months. Results: Regarding clinical outcome at end of chemotherapy, initial TMTV and TLG were found statistically significant (p 0.005) & (p 0.010) respectively. On multivariate analysis; ΔSUV max was found to be statistically significant (p <0.001). Regarding 2Y relapse free survival rate; initial 18F-FDG PET/CT TLG quantitative parameter was found statistically significant where 2Y-RFS rates for high- and low-TLG groups were 100% and 66.7% respectively (p 0.011). Conclusion: ΔSUV max was found to successfully predict clinical outcome at end of chemotherapy cycles. Initial 18F-FDG PET/CT TLG quantitative parameter successfully predict 2 Y-RFS. | ||
| Keywords | ||
| Non Hodgkin lymphoma; FDG PET/CT; Metabolic Parameters | ||
|
Statistics Article View: 259 PDF Download: 326 |
||
